Blog
RSS FeedPosted by Michael Wonder on 11 Apr 2024
NICE issues final draft guidance for use of remdesivir and also for tixagevimab-cilgavimab (Evusheld) for treatment of COVID-19
9 April 2024 - Final draft guidance for remdesivir and for tixagevimab with cilgavimab has been published by NICE. ...
Posted by Michael Wonder on 08 Apr 2024
SMC - April 2024 decisions
8 April 2024 - The SMC has today published advice on seven medicines. ...
Posted by Michael Wonder on 12 Mar 2024
SMC - March 2024 decisions
11 March 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...
Posted by Michael Wonder on 13 Feb 2024
SMC - February 2024 decisions
12 February 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...
Posted by Michael Wonder on 06 Feb 2024
Updates on NICE and SMC collaboration on MTA for cystic fibrosis
1 February 2024 - On 19 December 2023, we advised that NICE would be liaising with key stakeholders to determine ...
Posted by Michael Wonder on 22 Jan 2024
NICE issues draft guidance for use of remdesivir and also for tixagevimab-cilgavimab for treatment of COVID-19
18 January 2024 - Draft guidance for public consultation has been published by NICE. ...
Posted by Michael Wonder on 15 Jan 2024
SMC - January 2024 decisions
15 January 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...
Posted by Michael Wonder on 11 Dec 2023
SMC - December 2023 decisions
11 December 2023 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 13 Nov 2023
SMC - November 2023 decisions
13 November 2023 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 20 Oct 2023
Ethical and legal considerations in social media research for health technology assessment: conclusions from a scoping review
20 October 2023 - The objective was to identify and describe the published guidance and current academic discourse of ethical issues ...
Posted by Michael Wonder on 10 Oct 2023
Lynparza (olaparib) accepted for use in Scotland as adjuvant treatment for patients with germline BRCA mutated HER2 negative high risk early breast cancer
9 October 2023 - First and only approved medicine in Scotland which targets germline (hereditary) BRCA mutations in early breast cancer ...
Posted by Michael Wonder on 10 Oct 2023
AbbVie’s Aquipta (atogepant) is now available in Scotland for the prevention of migraines in adults
9 October 2023 - The SMC has accepted Aquipta (atogepant), the oral, once daily calcitonin gene-related peptide receptor antagonist for restricted ...
Posted by Michael Wonder on 09 Oct 2023
SMC - October 2023 decisions
9 October 2023 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...
Posted by Michael Wonder on 11 Sep 2023
SMC - September 2023 decisions
11 September 2023 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...
Posted by Michael Wonder on 07 Aug 2023
Scottish Medicines Consortium accepts Vazkepa (icosapent ethyl) to help reduce cardiovascular risk for patients in Scotland
7 August 2023 - Vazkepa already commercially available in England, Wales, and Northern Ireland where NICE recommended its reimbursement and use ...